Prolor CEO: It would make sense to find a partner

Prolor is seeking to become the first company to market a longer-lasting growth hormone.

FDA approves Teva's generic version of blood thinner Plavix

Brand Plavix has $6.7 billion in annual sales in the US.

Teva's board reelects Phillip Frost as chairman

Dr. Phillip Frost was unanimously elected for a second three-year term.

Life sciences salaries 30% lower than in high tech

Demand is growing for workers in the life sciences, including a 20% jump in demand for chemists.

Prolor Biotech raises net $35m in AMEX secondary offering

The company will use the proceeds for R&D and clinical trials, and maybe for acquisitions as well.

Rosetta Genomics skyrockets on Medicare coverage

Medicare will cover costs of the company's diagnostic test for cancer.

Healthcare expenses control co Simplee raises $6m

The Social+Capital Partnership and Greylock invested in the company's first financing round.

Stem cell co Gamida Cell raises $10m

The company will use the proceeds to support the commercialization of its StemEx, as an alternative therapeutic treatment for patients with blood cancers.

The Hurvitz life sciences legacy lives on

CHealth is the investment fund of Chaim Hurvitz, the son of the late Teva chairman Eli Hurvitz.

Tissue regeneration co Regentis Biomaterials raises $10m

The funds raised will be used to expand the company's clinical use of its innovative cartilage regeneration implant GelrinC.

Radiancy merger boosts Photomedex revenue

First quarter revenue rose 45% to $50.3 million, and the company forecasts $53 million second quarter revenue.

Demand for high-tech workers rises strongly

The latest exits have given the industry a boost, and mergers have improved workers' standing.

D Medical shares jump on OEM deal

South Korean diabetes products manufacturer Twobiens will distribute Spring Health infusion sets worldwide under its private label.

D-Pharm to cut salaries 25%

The cutbacks follow the failure of the Phase III clinical trial of the company's treatment for cerebral strokes.

Teva CFO: The new CEO will bring changes

Eyal Desheh told the Oppenheimer Israel conference that Teva plans launching 30 new products in the rest of 2012.

Candidates start lining up for Teva chairmanship

At Teva's results press conference, chairman Phillip Frost said he was a candidate for the job, implying others want it.

Protalix embarks on the next challenge

Marketing success isn't guaranteed, but CEO David Aviezer has a clear and ambitious vision for Protalix's future.

Bayer exec eager to conduct R&D in Israel

Bayer's SVP and head of global clinical development Jörg Müller tells "Globes" why the company likes working in Israel.

Merck Serono opens Israeli drug development incubator

Merck chairman Dr. Karl-Ludwig Kley tells "Globes" that the pharmaceutical company is building its presence in Israel.

Ignorance breeds volatility for life sciences shares

Research by Bioassociate Biotech Business Consulting found that investors do not understand the TASE notices of biomed companies.